FB_-1002

N/A

Report date: 2025/11/27 11:16:06
First In Class

Base Information

Drug NameFB_-1002
Drug Alias Name艾可宁和3BNC117FB_-1002FB-10024B02-01
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionTransmembrane glycoprotein gp41 inhibitorsHIV envelope protein gp120 inhibitorsNeurotrophic tyrosine kinase receptor type 2 activators
TargetsTransmembrane glycoprotein gp41HIV envelope protein gp120Neurotrophic tyrosine kinase receptor type 2
Therapy Area/IndicationsDepressive DisorderAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companies4b Technologies (Suzhou) Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active Companies4b Technologies (Suzhou) LtdFubei Biomedical Technology (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsDepressive DisorderAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A